Colorectal cancer in 2012: Revisiting landmark trials and identifying new therapies

Nature Reviews Clinical Oncology

Volumn 10, Issue 2, 2013, Pages 71-72

  Wu, Christina ^a   Goldberg, Richard M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AFLIBERCEPT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; REGORAFENIB;

ADJUVANT CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; OVERALL SURVIVAL; PRIMARY PREVENTION; PRIMARY TUMOR; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DISEASE MANAGEMENT; HUMANS; MOLECULAR TARGETED THERAPY; TIME FACTORS;

EID: 84873408271     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.227     Document Type: Review

References (10)

1. Burn, J. et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378, 2081-2087 (2011).
2. Sauer, R. et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J. Clin. Oncol. 30, 1926-1933 (2012).
3. Tournigand, C. et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J. Clin. Oncol. 30, 3353-3360 (2012).
4. Sanoff, H. K. et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J. Clin. Oncol. 30, 2624-2634 (2012).
5. Poultsides, G. A. et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receving combination chemotherapy without surgery as initial treatment. J. Clin. Oncol. 27, 3379-3384 (2009).
6. McCahill, L. E. et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. J. Clin. Oncol. 30, 3223-3228 (2012).
7. Van Cutsem, E. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30, 3499-3506 (2012).
8. Arnold, D. et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study) [abstract]. J. Clin. Oncol. 30 (Suppl.), aCRA3503 (2012).
9. Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. http://dx.doi.org/10.1016/S0140-6736(12)61900-X.
10. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).